{"id":370,"date":"2019-10-03T12:00:23","date_gmt":"2019-10-03T12:00:23","guid":{"rendered":"http:\/\/lr-cannabis.www.bioevents.net\/?page_id=370"},"modified":"2020-07-13T11:22:41","modified_gmt":"2020-07-13T11:22:41","slug":"dear-colleague","status":"publish","type":"page","link":"https:\/\/euroleuk.com\/dear-colleague\/","title":{"rendered":"Dear Colleague"},"content":{"rendered":"
Dear Colleague,<\/p>\n
It is with great pleasure that we invite you to attend The Virtual Congress on Controversies in Leukemias<\/strong> (EuroLeuk2020)<\/strong> which will take place 29-30 October 2020.<\/strong><\/p>\n This meeting will be valuable for you if you are looking for:<\/p>\n The meeting will provide clinicians and biologists with state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field and will be of interest to: The most relevant controversies on the following topics will be discussed: We look foward to welcoming medical professionals, treatment experts, industry leaders and other experts online.<\/p>\n Alessandro Isidori, MD, PhD,<\/strong> Dear Colleague, It is with great pleasure that we invite you to attend The Virtual Congress on Controversies in Leukemias (EuroLeuk2020) which will take place 29-30 October 2020. This meeting will be valuable for you if you are looking for: A cutting-edge scientific program \u2013 from basic science to clinical and therapeutic applications and perspectives […]<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-370","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n\n
\n\u2022 Senior or junior clinicians (MD, PhD, MD-PhD)
\n\u2022 Biologists (BS)
\n\u2022 Clinical residents in-training
\n\u2022 R&D personnel
\n\u2022 Pharmaceutical and industry professionals.<\/p>\n
\n\u2022 Biology of ALL, AML, CML, CLL
\n\u2022 Leukemia stem cells (LSCs)
\n\u2022 Routing diagnosis gene expression and mutational profiling
\n\u2022 Allogeneic hematopoietic stem cell transplantation
\n\u2022 Front-line treatment of ALL, AML, CML, CLL
\n\u2022 Treatment of resistant\/relapsed disease
\n\u2022 How novel agents are changing the treatment landscape of ALL, AML, CML and CLL
\n\u2022 Immunotherapy
\n\u2022 Minimal residual disease<\/p>\n<\/p>\n
\nHematology and Stem Cell Transplant Center<\/em>
\nMarche Nord Hospital \u2013 Pesaro – Italy<\/em>
\nCongress Chair<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"